Early Leukemia Detection

About Alercell

Alercell is a private, early-stage diagnostics company developing an AI-driven epigenetic platform for the ultra-early detection of leukemia and other cancers. Founded in 2018 and headquartered in New York, the company's bold claim is the ability to detect leukemia risk up to 41 months before symptom onset, targeting a paradigm shift from reactive treatment to proactive prevention. As a pre-revenue entity, its success hinges on clinical validation, regulatory approval, and market adoption of its novel diagnostic approach.

Therapeutic Areas